Zevra Therapeutics Inc. (ZVRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $550.42M
Last updated: Nov 17, 2026 at 4:17 PM ET
Zevra Therapeutics Inc. (ZVRA) Stock Chart
Zevra Therapeutics (ZVRA) has a latest price of $9.40 on Nov 17, 2026, 37.5% below its 52-week high of $15.04. Its price rose 5.9% over the past 12 months. The month-end price fell 82.6% over the 10 years through Oct 2026, a compound annual decline of 16.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $126.40 in Mar 2018 and its lowest $3.01 in May 2020, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ZVRA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ZVRA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 22.5%, and over 6 months it fell 7.8%. The month-end price rose 129.5% over the 3 years through Oct 2026, a compound annual rate of 31.9%.
| Period | Change |
|---|---|
| 1 month | -7.5% |
| 3 months | -22.5% |
| 6 months | -7.8% |
| 12 months | +5.9% |
| 12 months, with dividends | +5.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +129.5% | +31.9% |
| 5 years | +8.2% | +1.6% |
| 10 years | -82.6% | -16.1% |
Price by Year
Its best calendar year was 2020, when the price rose 84.7%, and its weakest was 2019, when it fell 78.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $10.28 | +14.7% |
| 2025 | $8.96 | +7.4% |
| 2024 | $8.34 | +27.3% |
| 2023 | $6.55 | +42.7% |
| 2022 | $4.59 | -47.3% |
| 2021 | $8.71 | -22.2% |
| 2020 | $11.20 | +84.7% |
| 2019 | $6.06 | -78.7% |
| 2018 | $28.48 | -56.0% |
| 2017 | $64.80 | +37.3% |
Trading Range
The price is 13.4% below its 50-day average of $10.86 and 13.4% below its 200-day average of $10.85.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $9.40 | |
| 52-week high | $15.04 | -37.5% |
| 52-week low | $8.01 | +17.4% |
| 50-day average | $10.86 | -13.4% |
| 200-day average | $10.85 | -13.4% |
Price Risk
Over 3 years, its largest fall from a peak was 43.5%.
| Measure | Value |
|---|---|
| 1-year beta | 1.03 |
| Largest fall, 1 year | -38.4% |
| Largest fall, 3 years | -43.5% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ZVRA
What is ZVRA's 1-year price change?
Zevra Therapeutics's price rose 5.9% over the past 12 months. With dividends included, the 12-month total return was 5.9%.
What is ZVRA's 5-year price change?
Zevra Therapeutics's month-end price rose 8.2% over the 5 years through Oct 2026, a compound annual rate of 1.6%. These figures leave out dividends.
What is ZVRA's 52-week high and low?
Zevra Therapeutics's 52-week high is $15.04 and its 52-week low is $8.01. Its latest price of $9.40 on Nov 17, 2026 is 37.5% below the high.
What is ZVRA's beta?
Zevra Therapeutics's 1-year beta against the S&P 500 is 1.03, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 38.4%.
Is the ZVRA chart free?
Yes. Advanced Charting for ZVRA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ZVRA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors